

Incorporating the Geriatric Assessment into Clinical Practice and Clinical Trials

4TH ANNUAL CANCER DISPARITIES SYMPOSIUM: DISPARITIES IN CANCER CARE FOR OLDER ADULTS

KATHRYN BYLOW, MD

Learning Objectives

To have a better understanding of:

- The predictive and therapeutic benefits of geriatric assessment in oncology patients
- Strategies for incorporating geriatric assessments in the oncology clinic
- Importance of incorporating geriatric assessments in clinical trials

Geriatric Assessment (GA) in the Care of Older Patients


PREDICTIVE AND THERAPEUTIC BENEFITS



The Cancer and Aging Crisis




Figure 1: Estimated cancer prevalence by age in the US population from 1975 (216 M) to 2040 (380 M)



Older patients are underrepresented in clinical trials

Ę



Talarico, et al. JCO 2004; 22:4626-31



"We have an ethical obligation to improve evidence development for older adults with cancer. Our society must deliver the best possible care for all patients, and a key requirement for this is to eliminate health disparities across all groups, including those defined by age, gender, race, and socioeconomic status. One of the most glaring disparities in the field of oncology is the lack of data to guide care for older adults."



Monica Bertagnolli, MD NCI Director

Why Does Age Matter?

Physiologic change with age	Result	· · · · · · · · · · · · · · · · · · ·
\downarrow Glomerular filtration rate	↑ Drug half life	AROUND THE BLOCK IN EIGHTY DAYS
↓ Cardiac reserve	↑ Cardiac toxicity	
\downarrow Mucosal protective mechanism	个 Mucositis	
\downarrow GI motility/blood flow/absorption	个 GI toxicity	
\downarrow Vital capacity of lung/impaired gas exchange	\uparrow Toxicity from radiation	
↑ Time to recovery of bone marrow	个 Myelosuppression	THE REAL PROPERTY OF THE PROPERTY OF THE REAL PROPE
个 Dementia/MCI	个 Delirium/AMS	G LANGILLE 97

Older Patients Have Unique Issues

There are many factors which add significant complexity when caring for the older adult with cancer

Comorbidity

Physical Function

Mental Health

Social Support

Nutrition

Polypharmacy



At 105 years of age, Mabel was an inspiration to smokers everywhere.

Geriatric Assessment Domains


Ę



"Last one to the top is a geriatric"

Domain	Instrument
Health	Comorbidity: Charlson,
	CIRS-G
Function	Performance Status, IADL, ADL, Falls, SPPB, TUG, Vision, Hearing
Cognition	MMSE, MoCA, Mini-Cog
Psych	Depression: GDS, PHQ-9
-	Anxiety: HADS, GAD-7
Social	Living conditions, caregiver status, income, transportation
Nutrition	MNA, BMI, unintentional weight loss
Pharmacy	Drug list and interaction

Goals of Geriatric Assessment: The 3 l's



Geriatric Assessment: The Concept

Stage the Age

- Chronological age ≠ Functional age
- Life expectancy should be estimated, taking into account comorbidities, disability, geriatric syndromes

Intervene based on GA-identified vulnerabilities

Precision Medicine for Aging

Not the Problem



VS



The Problem




VS




GA-Based Intervention and Outcome

Patient A

Patient B




GA-Based Intervention and Outcome



Potential Interventions for GA-Identified Impairments

Domain of Concern/Impairment	Potential Interventions
Physical Function/Mobility	Physical Medicine & Rehabilitation, PT/OT, Exercise Regimen, Home Safety Evaluation
Co-Morbidities	Coordination w/ Specialists to Optimize Medical Conditions, Evaluation of Life Expectancy
Social Function/Support	Transportation Resources, SW Involvement, Support Groups, Co-Pay Assistance Programs, Caregiver Support
Cognition	Involve Family/Caregiver, Delirium Prevention, Identify Healthcare Proxy, Referral to Neuropsychology
Psychological	Complementary/Integrative Medicine, Referral to Psychiatry/Psychology, Treat Anxiety/Depression, Spiritual Care
Nutrition	Dietary Recommendations, Supplemental Nutrition, Identify Local Resources
Polypharmacy	Medication Reconciliation, De-Prescribing, Evaluate for Potential DDI

Early Intervention is Key: Be Proactive



Pergolotti, M. ASCO 2021

The Data: GA Predicts Outcomes and Affects Decisions

Predicts treatment tolerance and overall survival (BRCA)

• Clough-Gorr, et al. JCO 2010, 28(3):380

Predicts grade 3-5 toxicity

• Hurria, et al. JCO 2011, 29(25):3457

Predicts overall survival (nomogram)

• Kanesvaran et al. JCO 2011, 29(27):3620

Predicts early death

• Soubeyran, et al. JCO 2012, 30(15):1829

Changes treatment decisions

• Caillet et al. JCO 2011, 29(27):3636

The Data: GA-based Interventions Improve Outcomes

GAP70+: GA Intervention to Reduce Treatment Toxicity in Older Patients with Advanced Cancer¹

- GA summary/recommendations vs usual care
- \downarrow Grade 3-5 toxicity, \downarrow falls, \uparrow medications stopped

GAIN: GA Intervention on Chemo-Related Toxic Effects in Older Adults with Cancer²

- GA + multidisciplinary input vs GA + usual care
- \downarrow Grade 3-5 toxicity, \uparrow advanced directive completion

INTEGERATE: Integrated GA and Treatment in Older People with Cancer Planned for Systemic Anti-Cancer Therapy³

- GA-driven integrated oncogeriatric care vs usual care
- \uparrow HRQOL, \downarrow hospitalizations, \downarrow treatment discontinuation

¹ Mohile et al. Lancet 2021. DOI: 10.1200/JCO.22.00738

² Li et al, JAMA Oncol 2021. DOI:10.1001/jamaoncol.2021.4158

³ Soo et al. JCO 2022. DOI:10.1016/S2666-7568(22)00169-6

VOLUME 32 · NUMBER 24 · AUGUST 20 2014

JOURNAL OF CLINICAL ONCOLOGY

REVIEW ARTICLE

International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer

Hans Wildiers, Pieter Heeren, Johan Flamaing, Cindy Kenis, and Koen Milisen, University Hospitals Leuven, KU Leuven, Leuven, Leuven, Belgium; Hans Wildiers, Pieter Heeren, Martine Puts, Ewa Topinkova, Maryska L.G. Janssen-Heijnen, Martine Extermann, Claire Falandry, Andrew Artz, Etienne Brain, Giuseppe Colloca, Johan Flamaing, Theodora Karnakis, Gindy Kenis, Sicardo A. Audusio, Supriya Mohile, Lazzaro Repetto, Barbara Van Leeuwen, Koen Milisen, and Arti Hurria


Older Adult Oncology, Version 1.2021 Featured Updates to the NCCN Guidelines

Efrat Dotan, MD¹⁺; Louise C. Walter, MD²⁺; Iene S. Browner, MD¹⁺; Katherine Clifton, MD¹⁺; Harvey Jay Cohen, MD¹⁺; Martine Externann, MD, PhD²; Cay Gross, MD²; Sumati Gupta, MD¹⁺; Genevieve Hollis, MSN, CRNP¹⁺, Joleen Hubbard, MD¹⁺; Reshma Jagit, MD, Dfhi¹⁺; Nancy L. Keating, MO, MPH¹⁺; Elizabeth Kessler, MD¹⁺; Joleen Hubbard, MD¹⁺; Beatri: Kore-Grodzicki, MD, PhD¹⁺; June M. McKoy, MD, MBA, JD, MPH¹⁺; Sumi Miara, MD¹⁺; Down, MD¹⁺; Tracey O'Connor, MD¹⁺; Cynthia Chwasu, MD, MS²⁺, Alehip Koake, MD²⁺; Marcia Russell, MD²⁺; Miara Sedrak, MD, MS²⁺; Fareeha Siddiqui, MD¹⁺; Arny Stella, MD²⁺; Derek L. Strewalt, MD²⁺; Ishwaria M. Subbish, MD, MS²⁺; Mlian P. Tew, MD¹⁺; Grant R. Williams, MD¹⁺; Liz Hollinger, ESN, RN²⁺; Giby V. George, MD²⁺; Maria Sussifi, MD, MS²⁺; Williams, P. Tew, MD¹⁺; Braneha Siddiqui, MD²⁺; Liz Hollinger, RSN, RN²⁺; Giby V. George, MD²⁺; Maria Sussifi, MD, MS²⁺; Williams, P. Tew, MD¹⁺; Lit KD¹⁺; Suni Niter, SMD²⁺; Derek L. Strewalt, MD¹⁺; Suni Nitera, MD²⁺; Suni Nitera, SMD¹⁺; Lit Hollinger, FSN, RN²⁺; Suni V. Storger, MD²⁺; Suni Nitera, SMD¹⁺; Lit Hollinger, RN²⁺; Am²⁺; Suni Nitera, MD²⁺; Suni Nitera, SMD¹⁺; Lit Hollinger, SM²⁺; SM²⁺; SMD¹⁺; Lit Hollinger, SM²⁺; Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update

William Dale, MD, PhD¹ (a); Heidi D, Klepin, MD, MS² (b); Grant R, Williams, MD, MSPH¹ (b); Shabbir M.H. Alibhai, MD⁴ (b); Cristiane Bergerot, PhD⁶ (c); Karlynn Brintzenhofeszoc, PhD, MSW² (b); Judith D, Hopkins, MD¹; Minaxi P, Jhawer, MD¹ (b); Vani Katheria, MS⁴ (b); Kah Poh Loh, MBBCh BAD, MS¹ (b); Lisa M. Lowenstein, PhD¹ (c); June M. McKsy, MD, PMP J, D, MBA² (c); Vanita Noronha, MD¹³ (c); Tanyanika Phillips, MD¹⁴, Ashley E, Rosko, MD¹⁵ (c); Tracy Ruegg, PhD, ANP¹⁴ (b); Medoly K, Schiaffino, PhD¹⁷; John F. Simmons Jr, MD¹⁸ (c); Ishwaria Subbiah, MD¹⁴ (c); William P, Tew, MD²⁴ (c); Tracy L Webb, PA-C¹¹ (c); Mary Whitehead, BFA²²; Mark R. Somerfield, PhD²³ (c); and Supriya G. Mohle, MD, MS¹⁰

DOI https://doi.org/10.1200/JC0.23.00933

GA is recommended by ASCO, NCCN, SIOG




Incorporating Geriatric Assessment in the Clinic

Geriatric Assessment: The Challenge

How do you fit GA in a very busy oncology clinic?


- Identify those at highest risk with screening tool
 - VES-13, G8
- ► Use EMR to screen if possible



Geriatric Assessment: The Challenge

What if you are in an area with limited resources?

- Maximize use of patient completed assessments
 - Use EMR when possible
- Use virtual visits to access subspecialty care when needed
 - Set up room with VV capability for those without computer/wifi access



https://www.mdcalc.com/calc/10426/g8-geriatric-screening-tool

Implementing GA in a busy clinic

DONE BEFORE VISIT

DONE DURING VISIT

Patient completes before visit	
ADLs, IADLs	
Fall risk (Have you fallen in the past 6 mo)	
Physical function assessment	
Depression/Anxiety	
Unintentional Weight loss	
Comorbidity assessment	
Social Support assessment	
Updates medications	


Staff does during visit	
CARG chemotherapy toxicity	Online form
Life expectancy	Online form
Cognitive assessment	In person eval (5 min)
Physical Assessment	In person eval (2-5 min)
Pharmacy Review	Pharmacist review pre or during visit

Online Resources

Screening for vulnerability/need for GA: G8	 <u>https://www.mdcalc.com/calc/10426/g8-geriatric-screening-tool</u>
Life expectancy: Lee Schonberg Index	 <u>https://eprognosis.ucsf.edu/leeschonberg.php</u>
Risk of chemotherapy toxicity: CARG chemo- toxicity calculator	 <u>https://www.mycarg.org/?page_id=2405</u>

Online Resources

CARG CHEMO-TOXICITY CALCULATOR



LEE SCHONBERG INDEX (LIFE EXPECTANCY)


Population: Community dwelling adults aged 50 and older English Español	Français Port	uguês
Outcome: All cause 4, 5, 10 and 14 year mortality		<u> </u>
Scroll to the bottom for more detailed information		
ta Calcultor		
. How old Is your patient?	80.84	
What is the sex of your patient?	Female	O Ma
. What is your patient's BM/P	*25	
Which best describes your patient's health in general?	Fair or Poor	
Does your patient have chronic lung disease, such as emphysema or chronic bronchitis?	@ Yes	O N
toes the lung disease limit usual activities (such as household chores or work) or require home oxygen?	e Yes	O N
. Has your patient ever had cancer (excluding minor skin cancers)?	O Yes	@ N
Does your patient have congestive heart failure?	O Yes	0 N
Does your patient have diabetes or high blood sugar?	O Yes	@ N
Which best describes your patient's cigarette use?	Former	Smoker
0. Does your patient have difficulty walking 1/4 mile (several city blocks) without help from other people or special equipm	went? 🛞 Yes	0.1
1. During the past 12 months, how many times was your patient hospitalized overnight?	Once	
 Boouve of a physical, mental or emotional problem, does your patient need the help of others in handling routine needs to ong necessary business, shopping, or getting around for other purposes? 	such as everyday househol	d chores,
	😨 Yes	O N
3. Because of a health or memory problem, does your patient have difficulty managing money - such as paying bills and keep		
4. Because of a health or memory problem, does your patient have difficulty with bathing or showering?	O Yes	No
S. Because of a health problem, does your patient have difficulty pushing or pulling large objects like a living room chair?	e Yes	O No
	Total Lee Index Point Total Schonberg Inde	

Incorporating Geriatric Assessment in Research

WE MUST DO BETTER


Older Patients 75+ on Clinical Trials

Ē




Hurria A et al. JCO 2014;32:2587-94

Older patients are underrepresented across tumor types



Older patients on trials are not representative of the general population



Older patients on trials are NOT representative of general population:

- Younger
- More fit
- Fewer comorbidities
- Less organ dysfunction

We don't know how to treat older patients with cancer

- Institute of Medicine (IOM) developed a committee to address the many issues facing the future of cancer care
 - <u>Delivering High-Quality Cancer Care: Charting a New Course for a System in</u> <u>Crisis (www.iom.edu/qualitycancercare</u>)
- One of the issues identified by this group was the need for evidence-based guidelines for the growing geriatric population who have cancer

01

Goal 1: Expand the <u>breadth</u> of data collected on cancer interventions for older adults and individuals with multiple comorbid conditions

 Bottom Line: Increase older patients on trial, especially 75 and older

02

Goal 2: Expand the <u>depth</u> of data available for assessing interventions

 Bottom line: Collect detailed information about comorbidity, functional status and QOL

IOM Goals and Recommendations

Strategies To Improve Data Collection in Clinical Trials



Use standardized GA measures and enhance data collection and reporting requirements to reflect endpoints relevant to older adults (QOL)



Assess frailty, comorbidities, meds for clinical trial participants (CGA)



Expand FDA authority to require submission of data for representative patient population



Expand FDA authority to require and enforce post-marketing commitments for studies of older adults

Strategies to incorporate GA in research

Develop	Develop trials specifically designed to enroll older adults
Include	Include a cohort of older patients in trials Parallel, stratified, embedded
Use	Use pragmatic design elements Inclusion/exclusion criteria, minimize visits needed
Increase	Increase number of trials in the community

Multidisciplinary Team Plays a Role

ISSUE	PROVIDER NEEDED
Cancer Care	Oncologist/APP/Nurse/MA
Comorbidity	Geriatrician/PCP/APP
Physical Function	Physical and Occupational Therapist/PMR
Mental Health	Psychiatrist/Psychologist
Social Situation	Social Worker
Nutrition	Dietician
Polypharmacy	Pharmacist
End of Life	Palliative Care/Spiritual Workers

Shortage of Providers for Older Patients with Cancer

- Potential shortfall of 1,500 oncologists in 2025
- It is estimated that approximately 30,000 geriatricians will be needed by 2030
 - Currently ~ 7500 geriatricians
- Less than 1% of RNs, pharmacists, and physician assistants and about 2.6% of APNPs are certified in geriatrics
- Approximately 4% of social workers specialize in geriatrics

WE NEED TO LEARN HOW TO DO THIS IN CLINIC WITHOUT SUBSPECIALTY HELP

0

Summary

- GA plays a key role in optimal care of older patients
- We need to incorporate GA in oncology clinics without the help of subspecialists
- We know shockingly little about how older patients with cancer tolerate systemic therapy
- Urgent need to increase breadth and depth of data for older patients with cancer
 - Incorporating GA in trials is critical

The time to act is NOW

G As older patients become the majority of the patients we evaluate and treat, they need to become the focus of our endeavors. Our elders deserve nothing less. **33**

—Stuart M. Lichtman, MD

Always remember...

